ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
+8.7%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$187M
AUM Growth
+$187M
(+11%)
Cap. Flow
+$18.6M
Cap. Flow
% of AUM
9.98%
Top 10 Holdings %
Top 10 Hldgs %
49.27%
Holding
34
New
9
Increased
10
Reduced
10
Closed
5
Top Buys
| 1 |
Tarsus Pharmaceuticals
TARS
|
$10.6M |
| 2 |
Revolution Medicines
RVMD
|
$7.41M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$7.3M |
| 4 |
Enliven Therapeutics
ELVN
|
$6M |
| 5 |
Applied Therapeutics
APLT
|
$5.26M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$11.7M |
| 2 |
Legend Biotech
LEGN
|
$8.64M |
| 3 |
Day One Biopharmaceuticals
DAWN
|
$7.39M |
| 4 |
Geron
GERN
|
$6.38M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$6.05M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $11M | 5.89% | 150,833 +21,833 | +17% | +$1.59M |
|
|
2
Tarsus Pharmaceuticals
TARS
$2.47B
| $10.6M | 5.67% | +321,898 | New | +$10.6M |
|
3
Merus
MRUS
$4.98B
| $10.4M | 5.57% | 208,244 +33,400 | +19% | +$1.67M |
|
4
CG Oncology
CGON
$2.04B
| $9.93M | 5.32% | 263,266 +88,390 | +51% | +$3.33M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $9.81M | 5.25% | 106,080 +30,442 | +40% | +$2.82M |
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $8.99M | 4.81% | 72,000 -1,500 | -2% | -$187K |
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $8.34M | 4.46% | 211,791 +42,422 | +25% | +$1.67M |
|
|
LBPH
8
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $8.03M | 4.3% | 240,892 +21,911 | +10% | +$730K |
|
9
Jasper Therapeutics
JSPR
$45.5M
| $7.51M | 4.02% | 399,466 +180,852 | +83% | +$3.4M |
|
|
10
Revolution Medicines
RVMD
$7.1B
| $7.41M | 3.97% | +163,500 | New | +$7.41M |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $7.3M | 3.91% | +227,700 | New | +$7.3M |
|
12
Tyra Biosciences
TYRA
$675M
| $6.35M | 3.4% | 270,075 +5,415 | +2% | +$127K |
|
|
CLYM
13
Climb Bio, Inc. Common Stock
CLYM
$151M
| $6.26M | 3.35% | 1,229,292 +729,292 | +146% | +$3.71M |
|
|
14
Geron
GERN
$893M
| $6.04M | 3.23% | 1,331,053 -1,405,610 | -51% | -$6.38M |
|
|
15
Enliven Therapeutics
ELVN
$1.2B
| $6M | 3.21% | +234,856 | New | +$6M |
|
16
Kura Oncology
KURA
$686M
| $5.75M | 3.08% | 294,081 -12,681 | -4% | -$248K |
|
|
17
Applied Therapeutics
APLT
$71M
| $5.26M | 2.81% | +618,332 | New | +$5.26M |
|
18
Edgewise Therapeutics
EWTX
$1.51B
| $5.01M | 2.68% | +187,695 | New | +$5.01M |
|
|
CNTA
19
Centessa Pharmaceuticals
CNTA
$2.25B
| $4.95M | 2.65% | +309,614 | New | +$4.95M |
|
20
Janux Therapeutics
JANX
$1.37B
| $4.94M | 2.65% | +108,811 | New | +$4.94M |
|
21
Disc Medicine
IRON
$2.07B
| $4.91M | 2.63% | 100,000 -66,500 | -40% | -$3.27M |
|
22
Perspective Therapeutics
CATX
$250M
| $4.56M | 2.44% | 341,739 -54,503 | -14% | -$728K |
|
23
MindMed
MNMD
$676M
| $4.49M | 2.4% | 788,508 -176,918 | -18% | -$1.01M |
|
|
ALMS
24
Alumis Inc. Common Stock
ALMS
$479M
| $4.47M | 2.39% | 418,416 -200,334 | -32% | -$2.14M |
|
25
Relay Therapeutics
RLAY
$619M
| $4.43M | 2.37% | +626,058 | New | +$4.43M |
|